MP0712 Enters SCLC Arena Against Approved DLL3 Rival: Mechanism Differentiates, But Evidence Vacuum Persists

Molecular Partners and Orano Med Dose First Patient in MP0712 SCLC Trial

Molecular Partners and Orano Med have announced the dosing of the first patient in their Phase I/IIa multi-centre US trial for MP0712. This novel radio-DARPin drug candidate targets the tumour-associated DLL3 protein, found in over 85% of small cell lung cancer (SCLC) tumours, delivering a 212Pb therapeutic payload. The trial aims to assess the safety and early efficacy of MP0712, with initial data expected in 2026 and comprehensive safety and efficacy findings projected for 2027. The study employs a "matched-pair" approach, combining diagnostic imaging with therapeutic dosing.

• MP0712 is a radio-designed ankyrin repeat protein (DARPin) specifically engineered to target the delta-like ligand 3 (DLL3) protein. This protein is highly expressed in over 85% of small cell lung cancer (SCLC) tumours, making it a promising target for therapeutic intervention. The drug carries a 212Pb therapeutic payload, designed to deliver targeted radiation to tumour cells expressing DLL3, thereby minimizing off-target effects and enhancing efficacy.
• The Phase I/IIa trial incorporates a unique "matched-pair" approach. This involves an initial imaging step using 203Pb-labelled MP0712 to predict tumour uptake, followed by therapeutic doses of 212Pb-labelled MP0712. Patients receive up to four doses according to assigned cohorts, with the first cohort already undergoing repeat dosing. This strategy aims to optimize treatment by ensuring the therapeutic agent reaches the intended target effectively.
• The collaboration between Molecular Partners and Orano Med leverages their respective expertise in DARPin technology and targeted alpha therapies. The successful dosing of the first patient marks a significant milestone, establishing the clinical safety profile of this novel therapy. Both companies anticipate reporting initial study data in 2026 and comprehensive findings in 2027, paving the way for further development of radio-DARPin candidates and expanding the potential of lead-212 in treating various cancer types.

Addressing SCLC's Unmet Needs with Novel Approaches

Small cell lung cancer (SCLC) remains one of the most therapeutically recalcitrant malignancies, characterized by rapid progression, early metastasis, and an almost universal pattern of relapse following initial treatment. Despite high initial response rates to platinum-based doublet chemotherapy, durable disease control is rarely achieved, and the overall prognosis remains poor across disease stages.

• Inevitable relapse and chemoresistance: Although platinum-containing doublets elicit responses in the majority of patients, relapse is inevitable and the tumor acquires profound resistance to subsequent therapies. Topotecan — with its limited efficacy — has persisted as the standard second-line option for approximately three decades, underscoring the absence of meaningful therapeutic advances in the relapsed setting.

• Paucity of druggable genomic targets: The SCLC genomic landscape offers few readily actionable alterations. Intratumoral and intertumoral heterogeneity, compounded by transcriptional plasticity, present substantial obstacles to effective targeting. Acquisition of tumor biopsies — particularly at relapse — further complicates molecular profiling efforts.

• Lack of validated predictive biomarkers: Biomarkers capable of selecting patients for novel targeted treatments or monitoring therapeutic responses have been largely absent. For PARP inhibitors specifically, current clinical results in SCLC are limited and predictive markers remain inconsistent across studies.

• Attenuated efficacy of immune checkpoint blockade (ICB): Although SCLC carries a high tumor mutation burden, the clinical benefit from ICBs is markedly less pronounced than in non-small cell lung cancer (NSCLC). SCLC exhibits a more immunodeficient phenotype, with low PD-L1 expression, downregulation of major histocompatibility complex (MHC) molecules, and dysregulation of regulatory chemokines that may facilitate immune escape. Most ICB studies in SCLC have been limited to early-phase trials and have failed to demonstrate superiority over conventional chemotherapy.

• Narrow foothold for immunotherapy approvals: Among ICB regimens, only atezolizumab in combination with chemotherapy demonstrated an overall survival benefit over chemotherapy alone in the phase III IMpower133 trial, leading to FDA approval as a first-line option for extensive-stage disease. The broader landscape of ICB combinations has not replicated this outcome at the phase III level.

• Persistent challenges with combination strategies and drug resistance: Multiple clinical trials evaluating novel combinations have failed to demonstrate positive survival outcomes. Challenges including drug resistance, toxicity, and limited single-agent efficacy have driven ongoing investigation into combination regimens and novel drug formulations, though results to date remain largely incremental.

Designing the MP0712 Phase I/IIa Trial for SCLC

The SCLC clinical trial landscape spans a broad range of therapeutic modalities — from cytotoxic chemotherapy combinations to immune checkpoint inhibitors and bispecific T-cell engagers — with trial designs evolving from traditional randomized Phase III frameworks toward biomarker-enriched and real-world evidence studies. Endpoints have consistently centered on OS and PFS, with ORR, DOR, and safety profiles serving as key secondary and exploratory measures across both interventional and meta-analytic designs.